Elicera Therapeutics AB (publ) (ELIC)
Free
No email, no account, no signup.
Pulling latest news for Elicera Therapeutics AB (publ)…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
Nasdaq First North Growth Market
Type
Biotech
Sector
Cell and gene cancer therapies
Market Cap
$15M
We're already tracking Elicera Therapeutics AB (publ) — here are the latest events we've registered
Recent News
- On April 21, 2026, Elicera announced a SEK 72.8 million rights issue to fund the CARMA study and clinical preparations for ELC-401. The company also reported that six out of eight patients in the CARMA study achieved a complete metabolic response. Additionally, CSO Magnus Essand was named 2026 Cancer Researcher of the Year by the Swedish Cancer Society.
Want to know how this news affects Elicera Therapeutics AB (publ)? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Elicera Therapeutics AB (publ) will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.